Genmab A/S · GMAB · Next earnings

Genmab A/S reports Tuesday, Feb 16, 2027

GMAB reports before market open with consensus EPS at $0.30 and revenue at $1.27B. Last quarter: Genmab pairs nine-month growth with a heavier launch agenda

Reports Before market open102 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.30 Calendar consensus
Consensus revenue $1.27B Calendar consensus
Report date Feb 16, 2027 Tuesday, date estimated
Session Before market open 102 days away

Where GMAB left off: FY2026 Q3

Full report

Genmab pairs nine-month growth with a heavier launch agenda

EPS surprise +55.6% Reported $0.56 vs $0.36
Revenue surprise -0.9% Reported $1.19B vs $1.20B
Stock move -4.3% Event window
Subsequent drift -0.0% Up to 20 sessions

No change to 2026 guidance; management expects revenue to finish at the upper end of the range.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory filings, reviews or approvals for Rina-S, petosemtamab and first-line EPKINLY may be delayed or not achieved.
  • The expected Q4 increase in operating expenses for launch activities creates execution risk.
  • Long-term safety, treatment duration and durability of response remain important uncertainties, particularly for petosemtamab.
  • Analysts raised questions about durability of response and overall-survival benefit, DARZALEX royalty expiration, and the timing and size of 2027 peak-sales estimates.

Questions analysts left open

  • Durability of response and overall-survival benefit for EPKINLY and petosemtamab.
  • The effect of DARZALEX royalty expiration on revenue.
  • Timing and scale of 2027 peak-sales estimates for three late-stage assets.

Ask FN2 about GMAB next report

Choose a question to continue your research
What should I watch for in GMAB's next earnings report?How did GMAB guide last quarter, and is consensus above or below that?Give me the bull and bear case going into GMAB earnings.

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Get the GMAB recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent GMAB quarters

All GMAB earnings
-4.3%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.